pcaf(p300/cbp-associated factor)

L-45 is the first potent and cell-active bromodomain (Brd) inhibitor of p300/CBP-associated factor (PCAF) (Kd: 126±15 nM).

High affinity and selective cell-permeable p300/CBP-associated factor (PCAF) inhibitor (Ki = 47 nM). Exhibits no significant activity against a panel of 48 other bromodomains except GCN5 (Kd = 600 nM). Exhibits >4500-fold selectivity for PCAF over BRD4. Also exhibits metabolic stability in mouse and human liver microsomes and no observable cytotoxicity in peripheral blood mononuclear cells (PBMC). Moustakim et al (2017) Discovery of a PCAF bromodomain chemical probe. Angew.Chem.Int.Ed. 56 827 PMID:27966810

NSC 698600 is a potent inhibitor of PCAF(p300/CBP-associated factor) with IC 50 of 6.51 μM that shows good inhibition activity of cancer cell proliferation [1].

NSC 694623 is a potent histone acetyltransferase (HAT) inhibitor with an IC50 of 15.9 μM against recombinant HAT p300/CBP-associated factor (PCAF) and exhibits anti-proliferative activity against certain cancer cells, making it useful for anti-cancer research.

PCAF-IN-1 is a highly selective PCAF (p300/CBP-associated factor) inhibitor with potential anti-tumor, anti-inflammatory, and anti-heart disease effects. Inhibition of PCAF attenuates cardiac remodeling after myocardial infarction, reduces polarization of M1-type macrophages, and attenuates autoimmune arthritis.

L-Moses (L-45) dihydrochloride is the first potent and selective inhibitor of the p300/CBP-associated factor (PCAF) bromodomain (Brd) with a dissociation constant (Kd) of 126 nM.

Anacardic Acid (6-pentadecylsalicylic Acid) is an effective inhibitor of p300 and p300/CBP-associated factor histone acetyltranferases. It also has antimicrobial activity, antibacterial activity, and inhibits prostaglandin synthase, lipoxygenase, and tyrosinase.